ArticleMedicine2026
Association of AISI and SIRI levels with mortality risk in patients with type 2 diabetes: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Inflammation plays a key role in complications and organ damage in type 2 diabetes mellitus (T2DM). The Aggregate Index of Systemic Inflammation (AISI) and Systemic Inflammation Response Index (SIRI) have emerged as potential markers for inflammation and prognosis. This study aimed to assess the association between AISI, SIRI levels, and mortality in T2DM patients. This study combined a population-level time-trend analysis using Global Burden of Disease data from 1990 to 2021 with a retrospective cohort study using National Health and Nutrition Examination Survey data from 1999 to 2018 linked to the National Death Index mortality files. The Global Burden of Disease data revealed an upward trend in T2DM incidence, with a slight decline in mortality rates from 2003 onward. In the National Health and Nutrition Examination Survey cohort, higher AISI and SIRI levels correlated with increased risks of cardiovascular disease (CVD) and all-cause mortality. After adjusting for confounders, the highest quartile of both indices (Q4) showed significantly higher mortality risks: for AISI quartile 4 (Q4) vs Q1, hazard ratio (HR) = 1.46 for CVD and HR = 1.71 for all-cause mortality; for SIRI Q4 vs Q1, HR = 1.98 for CVD and HR = 2.13 for all-cause mortality. These findings suggest AISI and SIRI may serve as simple markers for risk stratification in T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.